Research

For September 2018, we have selected:  Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persisten motor fluctuations (TOLEDO): a multicenter, double-blind, randomized, placebo-controlled trial. Lancet Neurol July 25, 2018. doi:10.1016/S1474-4422(18)30284-4. Subcutaneous infusion of apomorphine, a potent dopamine receptor agonist, is widely used in patients with Parkinson’s disease (PD) with motor fluctuations not optimally controlled with oral medication, but the previous evidence base to support this approach was weak, derived from open label studies.

Please find below articles from German authors and co-authors that were published in the European Journal of Neurology

For August 2018, we have selected: Corvol JC, Artaud F, Cornier-Dequaire F, et al., for the DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018. doi:10.1212/WNL.0000000000005816. Impulse control disorders (ICDs) are frequent in Parkinson’s disease (PD) patients, and can have relevant consequences on social life. Whereas the association between treatment with dopamine agonists (DA) and the onset of ICDs is well known, there is controversy about the relationship with dose and duration of DA therapy.

Despite its large use, recommendations for the use of brain F-18 FDG-PET in clinical practice were still lacking. The European Academy of Neurology (EAN) and the European Association of Nuclear Medicine (EANM) promoted a concerted action with 7 specialists from the two Societies and a group of facilitators in order to make the point on this issue. Extensive literature review and analysis of available data led, together with expert opinion (Delphi consensus), to deliver these recommendations that cover practically all the main brain neurodegenerative conditions causing cognitive impairment.

Please find below articles from Polish authors and co-authors that were published in the European Journal of Neurology

For July 2018, we have selected: Thomalla G, Simonsen CZ, Boutitie G, et al., for the WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. NEJM May 16, 2018. doi:10.1056/NEJMoa1804355. Thrombolysis is currently performed in patients with acute ischemic stroke within a window of 4.5 hours since the symptoms’ onset. In about one third of the patients, the exact time of stroke onset is unknown, like in patients who wake up from sleeping.

Please find below articles from Portuguese authors and co-authors that were published in the European Journal of Neurology

The celebrations of the Dystonia Europe 25th annniversary kicked off with a special lunch event in the European Parliament on 12 April. The 65 guests were welcomed by the Finnish Member of the European Parliament (MEP) Ms. Merja Kyllönen.  She… Continue Reading

Please find below articles from Belarusan authors and co-authors that were published in the European Journal of Neurology

For May 2018, we have selected: Kappos L, Bar-Or A, Cree BAC, et al., for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet Neurol 2018;391:1263-1273. Secondary progressive multiple sclerosis (SPMS) is characterized by a previous history of relapsing remitting MS (RRMS) and the continuous progression of disability over the years typically without relapses.

Please find below articles from French authors and co-authors that were published in the European Journal of Neurology

For April 2018, we have selected: Whelan CD, Altmann A, Botia JA, et al., for the ENIGMA-Epilepsy Working Group. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain 2018;141:391-408. Epilepsy affects 0.6-1.5% of the population worldwide with one-third of patients being resistant to antiepileptic treatment. Nowadays epilepsy is considered a network disorder in which several structural changes are involved.

by Prof. Radu Tanasescu   Paper: Maggi et al. ‘Central Vein Sign Differentiates Multiple Sclerosis from Central Nervous System Inflammatory Vasculopathies’. Annals of Neurology. 2018;83:283–294. Outline: This paper shows for the first time that central vein assessment in white matter… Continue Reading